Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immunologic destruction of normal platelets and insufficient production of platelets mediated by autoantibodies. And there are different treatment options for management of thrombocytopenia according to each case. Because of th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saeed H., Sayed H.M., Ramadan A., Nahla S. Kotb
Formato:	article
Lenguaje:	EN
Publicado:	Egyptian Society for Animal Management 2020
Materias:	immune thrombocytopenia (itp) rats romiplostim rituximab and thrombopoietin receptor agonists (tpo-ras) Zoology QL1-991 Veterinary medicine SF600-1100 Animal biochemistry QP501-801
Acceso en línea:	https://dx.doi.org/10.21608/javs.2019.20470.1000 https://doaj.org/article/40c8ab91f9484ff08280bb1be8c50ce7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:40c8ab91f9484ff08280bb1be8c50ce7
record_format	dspace
spelling	oai:doaj.org-article:40c8ab91f9484ff08280bb1be8c50ce72021-12-02T11:43:50ZToxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Ratshttps://dx.doi.org/10.21608/javs.2019.20470.10001687-40722090-3308https://doaj.org/article/40c8ab91f9484ff08280bb1be8c50ce72020-01-01T00:00:00Zhttps://javs.journals.ekb.eg/article_67859.htmlhttps://doaj.org/toc/1687-4072https://doaj.org/toc/2090-3308Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immunologic destruction of normal platelets and insufficient production of platelets mediated by autoantibodies. And there are different treatment options for management of thrombocytopenia according to each case. Because of the progression of the disease and its multiple pathophysiological pathways a combination of treatments used for management of ITP would be a point of interest. Co-administration of therapies may be useful in patients who are refractory to monotherapies and may result in a booster response because they target multiple mechanisms. Romiplostim is a potent drug used for the management of acute ITP and can be administered with other treatment options for ITP. The combination of Rituximab and Romiplostim may inhibit platelet destruction and at the same time increase platelet production. This combination can lead to a strong and a massive increase in platelet counts. In preclinical studies of Romiplostim safety margins could not be reliably estimated. Although some post marketing surveillance studies provided some information about the safety profile of this drug. More information is needed to evaluate drug interactions between Romiplostim and Rituximab.The goal of this study is to investigate the safety of co-treatment of Romiplostim with Rituximab as compared to each of these drugs in normal rats and thrombocytopenic rats. The measured safety parameters were evaluated for liver and kidney functions in normal and diseased groups of rats.The safety of this regimen should be taken in consideration, so that a balance between the harmful effects and beneficial response could be attained. Future studies are necessary to investigate the safety and efficacy balance of Romiplostim and Rituximab alone or in combination with each other for management of thrombocytopenia. Saeed H.Sayed H.M.Ramadan A.Nahla S. KotbEgyptian Society for Animal Managementarticleimmune thrombocytopenia (itp)ratsromiplostimrituximab and thrombopoietin receptor agonists (tpo-ras)ZoologyQL1-991Veterinary medicineSF600-1100Animal biochemistryQP501-801ENJournal of Applied Veterinary Sciences, Vol 5, Iss 1, Pp 1-10 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune thrombocytopenia (itp) rats romiplostim rituximab and thrombopoietin receptor agonists (tpo-ras) Zoology QL1-991 Veterinary medicine SF600-1100 Animal biochemistry QP501-801
spellingShingle	immune thrombocytopenia (itp) rats romiplostim rituximab and thrombopoietin receptor agonists (tpo-ras) Zoology QL1-991 Veterinary medicine SF600-1100 Animal biochemistry QP501-801 Saeed H. Sayed H.M. Ramadan A. Nahla S. Kotb Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats
description	Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immunologic destruction of normal platelets and insufficient production of platelets mediated by autoantibodies. And there are different treatment options for management of thrombocytopenia according to each case. Because of the progression of the disease and its multiple pathophysiological pathways a combination of treatments used for management of ITP would be a point of interest. Co-administration of therapies may be useful in patients who are refractory to monotherapies and may result in a booster response because they target multiple mechanisms. Romiplostim is a potent drug used for the management of acute ITP and can be administered with other treatment options for ITP. The combination of Rituximab and Romiplostim may inhibit platelet destruction and at the same time increase platelet production. This combination can lead to a strong and a massive increase in platelet counts. In preclinical studies of Romiplostim safety margins could not be reliably estimated. Although some post marketing surveillance studies provided some information about the safety profile of this drug. More information is needed to evaluate drug interactions between Romiplostim and Rituximab.The goal of this study is to investigate the safety of co-treatment of Romiplostim with Rituximab as compared to each of these drugs in normal rats and thrombocytopenic rats. The measured safety parameters were evaluated for liver and kidney functions in normal and diseased groups of rats.The safety of this regimen should be taken in consideration, so that a balance between the harmful effects and beneficial response could be attained. Future studies are necessary to investigate the safety and efficacy balance of Romiplostim and Rituximab alone or in combination with each other for management of thrombocytopenia.
format	article
author	Saeed H. Sayed H.M. Ramadan A. Nahla S. Kotb
author_facet	Saeed H. Sayed H.M. Ramadan A. Nahla S. Kotb
author_sort	Saeed H.
title	Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats
title_short	Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats
title_full	Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats
title_fullStr	Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats
title_full_unstemmed	Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats
title_sort	toxic interactions of romiplostim and rituximab in normal and thrombocytopenic rats
publisher	Egyptian Society for Animal Management
publishDate	2020
url	https://dx.doi.org/10.21608/javs.2019.20470.1000 https://doaj.org/article/40c8ab91f9484ff08280bb1be8c50ce7
work_keys_str_mv	AT saeedh toxicinteractionsofromiplostimandrituximabinnormalandthrombocytopenicrats AT sayedhm toxicinteractionsofromiplostimandrituximabinnormalandthrombocytopenicrats AT ramadana toxicinteractionsofromiplostimandrituximabinnormalandthrombocytopenicrats AT nahlaskotb toxicinteractionsofromiplostimandrituximabinnormalandthrombocytopenicrats
_version_	1718395336195571712

Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats

Ejemplares similares